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ABSTRACT
Objective Braces used to treat (PF) osteoarthritis (OA)
may reduce contact stress across the PF joint. We
hypothesised that in PF OA, braces would decrease knee
pain and shrink PF bone marrow lesions (BMLs).
Methods Eligible subjects had painful PF OA. Subjects
were randomly allocated to brace or no brace for 6 weeks.
Knee MRIs were acquired at baseline and 6 weeks. We
measured BMLs on post-contrast fat suppressed sagittal
and proton density weighted axial images. The primary
symptom outcome was change in pain at 6 weeks during
a preselected painful activity, and the primary structural
outcome was BML volume change in the PF joint.
Analyses used multiple linear regression.
Results We randomised 126 subjects aged 40–70 years
(mean age 55.5 years; 72 females (57.1%)). Mean
nominated visual analogue scale (0–10 cm) pain score at
baseline was 6.5 cm. 94 knees (75%) had PF BMLs at
baseline. Subjects wore the brace for a mean of 7.4 h/
day. 6 subjects withdrew during the trial. After
accounting for baseline values, the brace group had lower
knee pain than the control group at 6 weeks (difference
between groups −1.3 cm, 95% CI −2.0 to −0.7;
p<0.001) and reduced PF BML volume (difference
−490.6 mm3, 95% CI −929.5 to −51.7; p=0.03) but
not tibiofemoral volume (difference −53.9 mm3, 95%
CI −625.9 to 518.2; p=0.85).
Conclusions A PF brace reduces BML volume in the
targeted compartment of the knee, and relieves knee pain.
Trial registration number UK. ISRCTN50380458.
Symptomatic knee osteoarthritis (OA) affects
approximately 12.5% of the US and UK popula-
tions age ≥60 years1 2 and its prevalence is increas-
ing.3 There are few effective non-surgical
treatments and none has been consistently shown
to affect structural ﬁndings in the knee favourably.
New effective treatments are badly needed.
The main target of structural modifying trials has
been joint space loss on X-ray. Loss occurs slowly
and trials testing agents purported to delay that loss
require large numbers of patients followed for at
least 2 years.4 5 Further, knee OA progression is
driven by mechanical factors, such as meniscal tears
and malalignment across the joint, and drugs that
protect against joint space loss may not work in
this hostile mechanical environment.4 6 For these
and other reasons, OA trials targeting structure
modiﬁcation are challenging.
The use of MRI in knee OA studies has revealed
structural features that may be treatment targets.
Among these are bone marrow lesions (BMLs).
Histopathologic studies have shown that these lesions
represent areas of microfracture and ﬁbrosis beneath
the cortical bone surface7 and they have been aetio-
logically linked to bone trauma. They are caused, in
part, by excess focal stress (force per unit area) across a
localised area of the joint, such as occurs with malalign-
ment8 or a meniscal tear.9 Long term studies have
shown that these lesions predict adjacent cartilage
loss10; the development of knee pain correlates with
enlargement of these lesions11 and a decrease in knee
pain is related to their shrinkage.12 BMLs wax and
wane in size over a period as short as 6 weeks.13 Lastly,
one recent pilot randomised trial in patients with
painful knee OA14 showed that zoledronic acid,
a bisphosphonate, reduced knee pain and shrank
BMLs.
All of this suggests that BMLs may be good struc-
tural targets for treatments and that a successful strat-
egy to shrink them might be to reduce focal contact
stress across the joint. The knee comprises the tibiofe-
moral and patellofemoral (PF) joints. PF OA, a
common subtype,15 is a major cause of pain with
stair climbing, arising from a chair, and activities
involving kneeling or squatting. Like knee OA in
general, treatment of PF OA is limited. One potential
treatment is PF bracing. Unlike bulky braces for tibio-
femoral OA, these braces are sheer and ﬁt underneath
trousers. Powers et al16 has reported that, by pressing
the patella into the trochlear groove, PF braces
increase the contact area across the PF joint and thus
lessen contact stress; this is because, with the braces
on, force becomes distributed across a greater area.
To our knowledge, only one trial testing PF bracing
has been carried out, a comparative trial testing brace
with strap versus brace without strap, and this trial
showed no difference between the two conditions.17
If PF braces work by decreasing contact stress
across the osteoarthritic PF joint, they should, in
theory, shrink BMLs which are caused in part by
this contact stress. We performed a 6-week rando-
mised controlled trial testing the efﬁcacy of a patel-
lar brace on knee pain and BML volumes as
tracked by serial knee MRIs. Because there is no
evidence that PF braces affect tibiofemoral joint
BMLs which are caused by varus/valgus malalign-
ment, we also hypothesised that tibiofemoral BMLs
would not change with PF brace use.
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METHODS
Overview
We carried out a 6-week randomised trial of treatment with a
patellar brace for patients with painful PF OA. The primary out-
comes were knee pain during a nominated activity and structural
change using BML volume in the PF compartment. The trial
was carried out from August 2009 through September 2012.
Subjects
Subjects were recruited from primary and secondary care using
letters from general practitioners to knee OA patients, notices in
clinics, advertisements in local papers, and referrals from phy-
siotherapists. Subjects were enrolled if their knee radiographs were
scored by a musculoskeletal radiologist (CEH) as showing Kellgren
and Lawrence grade 2 or 3 in the PF joint (based on either lateral
or skyline ﬁlms), and if this was greater than the grade for the
tibiofemoral joint (these grades required at least probable narrow-
ing and deﬁnite osteophytes in the PF joint). Subjects were also
clinically assessed for PF joint symptoms such as pain with stair
climbing, kneeling, prolonged sitting or squatting (we will call
these aggravating activities), and on examination by an experienced
physiotherapist (MJC) they had to have lateral or medial patellar
facet tenderness or a positive patellar compression test. Pain must
have been present daily for the previous 3 months and had to be
sufﬁciently severe for a nominated aggravating activity to score 4
or above on a 0–10 cm visual analogue scale (VAS). If both knees
were eligible, we asked subjects to select their more symptomatic
knee. Potential participants had to be on stable medication for
3 months and were ineligible if they were initiating a new treat-
ment (such as physical therapy). They were asked to remain on the
baseline treatment regimen throughout the study and, if rando-
mised to therapy with a brace, were instructed on its use and asked
to wear it as many hours during the day as tolerated.
Exclusion criteria
Subjects were excluded if they had undergone previous patellar
surgery. We also excluded subjects with a history of known
meniscal or ligament injury, rheumatoid arthritis or other forms
of inﬂammatory arthritis, or an intra-articular steroid injection
into the painful knee in the previous month. For the purposes
of the MRI, patients were excluded if they had a cochlear
implant, metal objects in the body including a joint prosthesis, a
cardiac or neural pacemaker, a hydrocephalus shunt, an intra-
uterine contraceptive device or coil, if they had kidney dysfunc-
tion, or were undergoing renal dialysis. Contrast enhanced scans
were used in the study to facilitate the quantiﬁcation of synovial
volume. Given the use of these scans, we screened participants
for renal dysfunction and excluded those with estimated glom-
erular ﬁltration rate (eGFR) <45 mL/min. We allowed subjects
to enrol even if they did not have PF BMLs at baseline with the
anticipation that some would develop these lesions during the
trial.
Randomisation process
Randomisation at a ratio of 1:1 was by pre-prepared sealed
opaque envelopes under the supervision of the study statistician.
Study intervention
Active treatment consisted of a Bioskin Patellar Tracking Q Brace
(Ossur UK, Manchester, England; this brace is available throughout
the UK and can be seen at http://www.ossur.co.uk/injury-solutions/
products/knee/knee-sleeves-wraps/bioskin-q-brace-patella-tracking-
brace). At the baseline visit, subjects were randomly allocated to
brace or no brace for 6 weeks. The brace has a strap which can be
pulled over the patella or it can be worn without the strap. A recent
trial17 reported no difference in efﬁcacy between the strapped and
unstrapped conﬁguration. We allowed patients to select the
approach they preferred.
Outcome measures: pain
The primary symptom outcome measure was knee pain during
the pre-speciﬁed nominated activity. At the baseline examin-
ation, potential participants were asked to select an activity that
commonly caused them knee pain and this was checked to
make sure it was an activity likely to be related to PF OA. At
each visit, subjects completed a 0–10 cm VAS based on the
degree of knee pain experienced in the last 7 days during their
nominated aggravating activity.
Knee Osteoarthritis Outcome Score (KOOS): The KOOS
survey provided secondary pain outcomes. The KOOS is a vali-
dated, widely used, knee pain and function survey. We focused
on those for pain and function in activities of daily living (ADL)
subscales.18
Outcome measures: structure
PF BML volume: At baseline assessment, subjects underwent
contrast enhanced MRI of their trial knee and then obtained
MRIs again using the same protocol and same magnet at
6 weeks. We obtained MRIs with contrast to also assess synovial
volume (see below). We studied one knee per person. Using a
1.5 T Philips Gyroscan ACS NT (Philips, Best Netherlands), we
obtained axial proton density weighted (PDW) fat saturated (FS)
repetition time (TR) 1500 ms, echo time (TE) 15 ms, ﬁeld of
view (FOV) 16 cm, 256×256 matrix, slice thickness 3 mm with
0.3 mm gap, and T1 weighted sagittal post-contrast scans FS TR
500 ms, TE 17 ms, FOV 16 cm, 384×384 matrix, slice thick-
ness 3 mm with 0.3 mm gap in all subjects. The contrast agent
was Dotarem (gadoteric acid) at a dose of 0.2 mg/kg.
Post-contrast images have been shown19 to provide assessments
of BMLs similar to PDW FS non-contrast enhanced images.
After initial training from a musculoskeletal radiologist
(CEH) on the appearance and size of BMLs and on distinguish-
ing BMLs from non-BML lesions, technicians at iMorphics
manually segmented BML volumes in paired images from each
subject’s knee. BMLs were outlined on each MRI slice and the
volume integrated over all slices. During the process of segmen-
tation, the radiologist reviewed any lesions where questions
were raised about the nature and size of the lesion, and either
he or an experienced radiology trainee (EJM) reviewed all knees
showing at least 50% change in BML volume and a random
sample of other knees to ensure that these changes were, in
reality, changes in BML volumes. As a result of this review,
roughly 30% of knees underwent repeat segmentations. For the
axial images only, we focused on the patella and femur only. For
sagittal images, we segmented BMLs in the patella, femur and
tibia. Staff measuring BMLs or other MRI features were blinded
to time points and to treatment assignment.
Results were based on the sagittal scan measurements except
for the initial 11 patients, who did not obtain these pulse
sequences, in which case we used the axial scans (failure to
acquire sagittal scans precluded measurement of tibiofemoral
BMLs and synovitis in these knees). Interobserver reliability for
BML volume was intraclass correlation coefﬁcient (ICC)=0.91
(p<0.001).
The primary structural outcome was change in PF BMLs. We
deﬁned BMLs in the PF joint as those involving the patella or
the opposing region of the anterior femur using regions derived
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from the Whole-Organ Magnetic Resonance Imaging Score
(WORMS) scale20 (ﬁgure 1).
We also studied one control structural outcome we hypothe-
sised would not change with treatment, tibiofemoral BML
volume, which we determined by taking the whole knee’s BML
volume and subtracting the PF BML volume.
In addition, we examined a secondary structure outcome, syn-
ovial volume. Fluctuation in synovial volume has also been tied
to change in knee pain severity,21 22 and our contrast-enhanced
scans provided us the opportunity to characterise change in syn-
ovial volume. Synovial volume was segmented using the same
strategy as BML volumes. Reliability of measurement was
ICC=0.89 (p<0.001).
Monitoring adverse events
At the baseline visit, participants were provided with contact
information for study staff and asked to call with any problems
regarding brace treatment. At the 6-week visit, subjects were
asked directly whether they had had any problems or side
effects with treatment.
Sample size
The study was powered to test whether the effects of bracing on
pain are mediated by structural changes induced by the brace,
using the methods described by Fritz and MacKinnon.23
We assumed a moderate effect of bracing on BMLs (an improve-
ment in BML volume of 0.5 SDs in the braced group compared
Figure 1 (A) Patellofemoral bone marrow lesions on MRI (arrows). (B) Regions deﬁning patellofemoral and tibiofemoral bone marrow lesions.
Table 1 Baseline characteristics of patients in the brace trial
Statistic
No Brace Group (N=63)
mean (SD)
Brace Group (N=63)
mean (SD)
Age 56.4 (8.1) 54.5 (6.7)
% Female 50.8% 63.5%
BMI (kg/m2) 30.5 (5.1) 31.4 (6.3)
Baseline pain on nominated activity VAS (0–10 cm) 6.3 (2.1) 6.8 (2.1)
Baseline KOOS pain subscale score (100–0) 51.1 (18.4) 48.2 (18.4)
Baseline KOOS ADL subscale score (100–0) 57.0 (19.2) 52.7 (22.0)
Total bone marrow lesion volume (mm3)—all patients 4460.4 (6322.0) 5816.5 (7686.9)
Patellofemoral bone marrow lesion volume—all patients 2088.1 (2938.8) 3039.4 (3974.9)
Tibiofemoral bone marrow lesion volume—all patients 2372.3 (6010.5) 2777.1 (5338.4)
Total bone marrow lesion volume (mm3)—patients with BMLs only 4606.7 (6373.0) 6439.7 (7838.9)
Patellofemoral bone marrow lesion volume—patients with BMLs only 2859.9 (3105.4) 3925.9 (4117.3)
Tibiofemoral bone marrow lesion volume—patients with BMLs only 3933.0 (7364.1) 4531.1 (6230.6)
Bone marrow lesion prevalence (N, %): – –
Patients with no bone marrow lesions (whole knee) 2, 3.2% 6, 9.7%
Patients with no patellofemoral bone marrow lesions 17, 27% 14, 22.6%
Patients with no tibiofemoral bone marrow lesions 25, 39.7% 24, 38.7%
Total synovitis volume (mm3) 29 807.5 (14 469.4) 29 651.5 (13 570.1)
Synovitis prevalence (N, %): – –
Patients with no synovitis (whole knee) 0, 0% 0, 0%
All figures are presented as mean (SD) unless otherwise specified.
ADL, activities of daily living; BMI, body mass index; BML, bone marrow lesion; KOOS, Knee Osteoarthritis Outcome Score; VAS, visual analogue scale.
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Figure 2 Consort diagram for the brace trial. DVT, deep vein thrombosis; eGFR, estimated glomerular ﬁltration rate; Gado, gadolinium;
K-L, Kellgren-Lawrence; PFJ, patellofemoral joint; TFJ, tibiofemoral joint.
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to non-braced) and a moderate effect of BMLs on pain (R2 for
regression of 0.13). Using a two-sided α of 0.05, and assuming
80% power, 120 subjects would be sufﬁcient to detect the
mediated effect.
Statistical analysis
We used an analysis of covariance (ANCOVA) approach to paral-
lel group trial analysis, to assess between-groups differences.24
Six linear regression models were constructed. Each model con-
sisted of one of the outcome variables of interest (eg, pain in
nominated activity) at follow-up as the dependent variable, with
treatment group as the independent variable and baseline value
of the outcome as a covariate. We used an intention-to-treat
approach with the last observation carried forward. We also
carried out complete case analyses as a sensitivity analysis.
Robust standard errors were used, after model residuals sug-
gested evidence of heteroskedasticity. To examine the association
of change in pain with change in BML volume, we used linear
regression. Statistical analysis was performed using Stata (V.13.1;
Stata Corporation, College Station, Texas, USA), with an α level
of 0.05 (two-sided) for the assessment of statistical signiﬁcance.
The study was approved by the Central Manchester Local
Research Ethics Committee (Ethics number 09/H1012/35) and
Wellcome Trust Clinical Research Facility, Scientiﬁc Advisory
Board. Subjects provided written consent before randomisation.
(UK. ISRCTN50380458.)
RESULTS
One hundred and twenty-six participants were randomised to
brace or no brace. Subjects ranged in age from 40–70 year
(mean 55.5 years; SD 7.5). There were 72 females (57.1%). The
two groups were similar in terms of demographics and disease
measures (table 1). Mean nominated visual analogue scale (0–10
cm) pain score at baseline was 6.5 cm. Participants reported a
mean of 7.4 h/day (SD 2.5) of brace use after 6 weeks of treat-
ment. Of the patients who provided data on their patellar strap
use, 66% chose not to wear the patellar support strap.
Seventy-ﬁve per cent of trial knees (94/125) had PF BMLs at
baseline.
Six subjects withdrew during the 6-week trial (4.8%) and
were not included in the complete case analysis of pain out-
comes (ﬁgure 2). One subject did not obtain usable MRI images
at baseline and thus 125 participants were randomised in the
structural outcomes component of the study. Of these, ﬁve were
among the six who withdrew and an additional three chose not
have to have MRIs again at 6 weeks, precluding analysis of
change. Thus, 117 subjects had baseline and 6-week images.
One subject had a serious adverse event, bilateral leg swelling,
which was felt to be unrelated to treatment (the brace was used
on one knee). No other adverse events were reported.
Pain and symptoms
Compared with the no brace group, the brace group showed a
signiﬁcant improvement in nominated activity pain and in the
KOOS subscales (table 2). The results for complete case analysis
were similar.
Change in structural outcomes
After accounting for baseline values, the brace group had PF
BML volumes 490.6 mm3 smaller than the group without the
brace, representing an 18% smaller volume (table 3). This dif-
ference between groups was statistically signiﬁcant (p=0.03).
Similarly, in the complete case analysis, the brace group had PF
BML volumes at 6 weeks that were 19.4% smaller than the
group not given a brace (p=0.03), after controlling for baseline
values. In both intent to treat and complete case analyses, there
was a non-signiﬁcant difference in tibiofemoral BML volumes
between the two groups. Lastly, in intent to treat and complete
case analyses, synovial volume differed modestly (5–6%)
between both treatment groups. Of those who did not have
PF BMLs at baseline, three developed BMLs during the trial,
and all three were in the no brace group. We found the same
trend toward reduction in PF BMLs in those knees where we
used sagittal scans and ones where we had only axial scans.
Change in pain on nominated activity was not signiﬁcantly
associated with change in PF BML volume (β coefﬁcient for
change in PF BML volume of 1000 mm3=0.2 cm, 95% CI −0.1
to 0.4 cm; p=0.17). We also found no signiﬁcant relation of
change in pain with change in overall BML volume, or with
change in synovial volume.
DISCUSSION
In this trial, we found that a PF brace reduced pain in patients
with PF OA over a 6-week period. Perhaps more importantly,
this brace was associated with a reduced volume of PF BMLs
compared with the control. Furthermore, tibiofemoral BML
volumes did not differ at follow-up, suggesting that the reduced
PF BML volume was speciﬁc to the treated knee compartment.
Synovial volume change did not differ between treatment
groups. We did not ﬁnd a signiﬁcant relationship between
change in pain and change in any of the MRI parameters.
It has long been thought that much of the pain associated
with OA emanates from bone25 which is richly innervated with
nociceptive ﬁbres. BMLs were noted to be common in knee OA
over a decade ago and have been associated with knee pain.26
Longitudinal studies have suggested that when these lesions
enlarge, pain worsens, and that when they shrink, pain gets
better.12 Further, these lesions have been linked to subsequent
cartilage loss, usually superﬁcial to the lesion.10 The histopath-
ology of these lesions suggest they are caused by traumatic focal
Table 2 Results for symptom outcomes: intent to treat analysis (N=125/126/123 for nominated VAS, KOOS pain, and KOOS ADL subscales,
respectively)
Variable
No brace Brace Between groups difference
Mean at follow-up, when controlling
for baseline value (95% CI)
Mean at follow-up, when controlling
for baseline value (95% CI)
Brace/no brace
difference (95% CI) p Value
Primary outcome: nominated VAS (0–10 cm) 6.3 (5.9 to 6.8) 5.0 (4.5 to 5.5) −1.3 (−2.0 to −0.7) <0.001
KOOS pain subscale (100–0)* 51.8 (48.6 to 54.9) 57.5 (53.5 to 61.5) 5.7 (0.6 to 10.8) 0.03
KOOS ADL subscale (100–0)* 56.3 (53.4 to 59.2) 60.8 (58.0 to 63.6) 4.5 (0.5 to 8.5) 0.03
*Increase in KOOS score represents improvement.
ADL, activities of daily living; KOOS, Knee Osteoarthritis Outcome Score; VAS, visual analogue scale.
1168 Callaghan MJ, et al. Ann Rheum Dis 2015;74:1164–1170. doi:10.1136/annrheumdis-2014-206376
Clinical and epidemiological research
stress to the bone, and reducing focal stress across the joint
should cause them to shrink.
The effect of the brace on pain was modest and the mean dif-
ference in pain change versus control was close to the threshold
for the minimal clinically important difference for VAS pain,
which has varied in different studies.
Bracing has not been widely tested for knee OA. In two of
three published trials,27 28 valgus bracing for persons with
medial knee OA reduced knee pain, although none of these
studies examined structural changes. Patellar bracing, which is
better tolerated than valgus bracing, has not, to our knowledge,
been tested either against placebo or no treatment in a rando-
mised trial. We might have compared patellar bracing against
placebo. However, any attempt to enclose the knee in a sleeve
or brace could have pushed the patella in and would not have
served as an inert placebo. In unpublished work carried out in
trial participants using an open MRI, we found that even patel-
lar taping, which can relieve PF pain,29 alters patellar position,
suggesting that it also would not be an appropriate placebo. We
decided therefore to use structural changes to demonstrate
effects of the patellar brace.
There was a modest non-signﬁcant association of change in
pain with change in PF BMLs. Our failure to ﬁnd this associ-
ation is at odds with the other trial using BMLs as an
outcome.14 Our results, and those of Zhang et al,12 suggest that
the relationship of pain and change in BML volume is modest
and would require a much larger sample size than ours.
Our study has several limitations. Most importantly, knee OA
is a chronic long term condition. Our 6-week study provides
little insight into whether longer term pain or structural deteri-
oration can be affected by this or any other treatment. Work
tying these short term to longer term ﬁndings is needed.
However, it is critical to demonstrate that structural changes can
occur quickly in OA as this opens the door to testing many
more putative treatments than heretofore feasible. Trials target-
ing hyaline cartilage protection have had to be large and long
term with daunting expense and challenging feasibility, and this
has discouraged treatment development. Targeting BMLs may
offer an achievable alternative that may expedite and facilitate
testing of new treatments.
Our trial focused on a mechanical treatment but, as a recent
trial of zoledronic acid14 suggests, BMLs may respond to
medical treatments. However, our results point to the opportun-
ity that exists for mechanical treatments in a disease where a
large component of the pathology is driven by abnormal joint
loading.
In conclusion, this trial of bracing for PF OA has suggested
that a brace may relieve pain in affected patients. Perhaps more
importantly, it suggests that BMLs, a common structural accom-
paniment of disease, may be treatable.
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*This includes knees with no BMLs in the region at baseline.
BML, bone marrow lesion.
Callaghan MJ, et al. Ann Rheum Dis 2015;74:1164–1170. doi:10.1136/annrheumdis-2014-206376 1169
Clinical and epidemiological research
9 Englund M, Guermazi A, Roemer FW, et al. Meniscal pathology on MRI increases
the risk for both incident and enlarging subchondral bone marrow lesions of the
knee: the MOST Study. Ann Rheum Dis 2010;69:1796–802.
10 Hunter DJ, Zhang Y, Niu J, et al. Increase in bone marrow lesions associated with
cartilage loss: a longitudinal magnetic resonance imaging study of knee
osteoarthritis. Arthritis Rheum 2006;54:1529–35.
11 Felson DT, Niu J, Guermazi A, et al. Correlation of the development of knee pain
with enlarging bone marrow lesions on magnetic resonance imaging. Arthritis
Rheum 2007;56:2986–92.
12 Zhang Y, Nevitt M, Niu J, et al. Fluctuation of knee pain and changes in bone
marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis
Rheum 2011;63:691–9.
13 Felson DT, Parkes MJ, Marjanovic EJ, et al. Bone marrow lesions in
knee osteoarthritis change in 6–12 weeks. Osteoarthritis Cartilage
2012;20:1514–18.
14 Laslett LL, Dore DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone
marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis
2012;71:1322–8.
15 Duncan R, Peat G, Thomas E, et al. Does isolated patellofemoral osteoarthritis
matter? Osteoarthritis Cartilage 2009;17:1151–5.
16 Powers CM, Ward SR, Chen YJ, et al. The effect of bracing on patellofemoral joint
stress during free and fast walking. Am J Sports Med 2004;32:224–31.
17 Hunter DJ, Harvey W, Gross KD, et al. A randomized trial of patellofemoral bracing
for treatment of patellofemoral osteoarthritis. Osteoarthritis Cartilage
2011;19:792–800.
18 Roos EM, Roos HP, Lohmander LS, et al. Knee Injury and Osteoarthritis Outcome
Score (KOOS)—development of a self-administered outcome measure. J Orthop
Sports Phys Ther 1998;28:88–96.
19 Roemer FW, Hunter DJ, Guermazi A. MRI-based semiquantitative assessment of
subchondral bone marrow lesions in osteoarthritis research. Osteoarthritis Cartilage
2009;17:414–15.
20 Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging
Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004;12:177–90.
21 Hill CL, Hunter DJ, Niu J, et al. Synovitis detected on magnetic resonance imaging
and its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis
2007;66:1599–603.
22 Ostergaard M, Ejbjerg B, Stoltenberg M, et al. Quantitative magnetic resonance
imaging as marker of synovial membrane regeneration and recurrence of synovitis
after arthroscopic knee joint synovectomy: a one year follow up study. Ann Rheum
Dis 2001;60:233–6.
23 Fritz MS, Mackinnon DP. Required sample size to detect the mediated effect.
Psychol Sci 2007;18:233–9.
24 Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and
follow up measurements. BMJ 2001;323:1123–4.
25 Arnoldi CC, Lemperg K, Linderholm H. Intraosseous hypertension and pain in the
knee. J Bone Joint Surg Br 1975;57:360–3.
26 Yusuf E, Kortekaas MC, Watt I, et al. Do knee abnormalities visualised on MRI explain
knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis 2011;70:60–7.
27 Kirkley A, Webster-Bogaert S, Litchﬁeld R, et al. The effect of bracing on varus
gonarthrosis. J Bone Joint Surg Am 1999;81:539–48.
28 Hunter D, Gross KD, McCree P, et al. Realignment treatment for medial tibiofemoral
osteoarthritis: randomised trial. Ann Rheum Dis 2012;71:1658–65.
29 Quilty B, Tucker M, Campbell R, et al. Physiotherapy, including quadriceps
exercises and patellar taping, for knee osteoarthritis with predominant
patello-femoral joint involvement: randomized controlled trial. J Rheumatol
2003;30:1311–17.
1170 Callaghan MJ, et al. Ann Rheum Dis 2015;74:1164–1170. doi:10.1136/annrheumdis-2014-206376
Clinical and epidemiological research
